Stocks and Investing Stocks and Investing
Tue, August 15, 2023

Robyn Karnauskas Maintained (BTAI) at Strong Buy with Decreased Target to $31 on, Aug 15th, 2023


Published on 2024-10-28 05:54:42 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $71 to $31 on, Aug 15th, 2023.

Robyn has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 1 agrees with Robyn's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023


This is the rating of the analyst that currently disagrees with Robyn


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $60 on, Monday, July 3rd, 2023

Contributing Sources